Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group

Borchmann, Peter, Prof ; Haverkamp, Heinz, Dipl-Math ; Lohri, Andreas, MD ; Mey, Ulrich, MD ; Kreissl, Stefanie, MD ; Greil, Richard, Prof ; Markova, Jana, MD ; Feuring-Buske, Michaela, MD ; Meissner, Julia, MD ; Dührsen, Ulrich, Prof ; Ostermann, Helmut, Prof ; Keller, Ulrich, MD ; Maschmeyer, Georg, Prof ; Kuhnert, Georg, MD ; Dietlein, Markus, Prof ; Kobe, Carsten, MD ; Eich, Hans, Prof ; Baues, Christian, MD ; Stein, Harald, Prof ; Fuchs, Michael, MD ; Diehl, Volker, Prof ; Engert, Andreas, Prof

The lancet oncology, 2017-04, Vol.18 (4), p.454-463 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível